February 4, 2020

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, N.E.

Washington, DC 20549

 

Re:Can-Fite BioPharma Ltd.

Registration Statement on Form F-1 (File No. 333-236064)

Concurrence in Acceleration Request

 

Ladies and Gentlemen:

 

H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Can-Fite BioPharma Ltd. that the effective date of the above-referenced registration statement be accelerated to 9:00 a.m. (Eastern Time), or as soon as practicable thereafter, on February 5, 2020, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

 

H.C. WAINWRIGHT & CO., LLC  
   
By: /s/ Edward D. Silvera  
  Name: Edward D. Silvera  
  Title: Chief Operating Officer  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

430 Park Avenue | New York, New York 10022 | 212.356.0500

Security services provided by H.C. Wainwright & Co., LLC | Member: FINRA/SIPC